Department of Urology, New York University School of Medicine, New York.
Department of Population Health, New York University School of Medicine, New York.
JAMA Netw Open. 2018 Aug 3;1(4):e181172. doi: 10.1001/jamanetworkopen.2018.1172.
Prostate cancer imaging rates appear to vary by health care setting. With the recent extension of the Veterans Access, Choice, and Accountability Act, the government has provided funds for veterans to seek care outside the Veterans Health Administration (VA). It is important to understand the difference in imaging rates and subsequent differences in patterns of care in the VA vs a traditional fee-for-service setting such as Medicare.
To assess the association between prostate cancer imaging rates and a VA vs fee-for-service health care setting.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study included data for men who received a diagnosis of prostate cancer from January 1, 2004, through March 31, 2008, that were collected from the VA Central Cancer Registry, linked to administrate claims and Medicare utilization records, and the Surveillance, Epidemiology, and End Results Program database. Three distinct nationally representative cohorts were constructed (use of VA only, use of Medicare only, and dual use of VA and Medicare). Men older than 85 years at diagnosis and men without high-risk features but missing any tumor risk characteristic (prostate-specific antigen, Gleason grade, or clinical stage) were excluded. Analysis of the data was completed from March 2016 to February 2018.
Patient utilization of different health care delivery systems.
Rates of prostate cancer imaging were analyzed by health care setting (Medicare only, VA and Medicare, and VA only) among patients with low-risk prostate cancer and patients with high-risk prostate cancer.
Of 98 867 men with prostate cancer (77.4% white; mean [SD] age, 70.26 [7.48] years) in the study cohort, 57.3% were in the Medicare-only group, 14.5% in the VA and Medicare group, and 28.1% in the VA-only group. Among men with low-risk prostate cancer, the Medicare-only group had the highest rate of guideline-discordant imaging (52.5%), followed by the VA and Medicare group (50.9%) and the VA-only group (45.9%) (P < .001). Imaging rates for men with high-risk prostate cancer were not significantly different among the 3 groups. Multivariable analysis showed that individuals in the VA and Medicare group (risk ratio [RR], 0.87; 95% CI, 0.76-0.98) and VA-only group (RR, 0.79; 95% CI, 0.67-0.92) were less likely to receive guideline-discordant imaging than those in the Medicare-only group.
The results of this study suggest that patients with prostate cancer who use Medicare rather than the VA for health care could experience more utilization of health care services without an improvement in the quality of care.
前列腺癌的影像学检查率似乎因医疗保健环境而异。随着《退伍军人医疗保健选择和问责法案》的最近扩展,政府为退伍军人提供了在退伍军人事务部(VA)之外寻求医疗服务的资金。了解 VA 与传统按服务收费的医疗保健环境(如 Medicare)之间影像学检查率的差异以及随后的护理模式差异非常重要。
评估前列腺癌影像学检查率与 VA 与按服务收费医疗保健环境之间的关联。
设计、设置和参与者:这项队列研究纳入了 2004 年 1 月 1 日至 2008 年 3 月 31 日期间被诊断为前列腺癌的男性的数据,这些数据来自 VA 中央癌症登记处,与管理索赔和 Medicare 利用记录以及监测、流行病学和最终结果计划数据库相链接。构建了三个具有代表性的全国性队列(仅使用 VA、仅使用 Medicare 以及同时使用 VA 和 Medicare)。排除了 85 岁以上诊断的男性和没有高危特征但缺少任何肿瘤风险特征(前列腺特异性抗原、Gleason 分级或临床分期)的男性。数据分析于 2016 年 3 月至 2018 年 2 月进行。
患者使用不同的医疗保健提供系统。
在低危前列腺癌患者和高危前列腺癌患者中,按医疗保健环境(仅 Medicare、VA 和 Medicare 以及仅 VA)分析前列腺癌影像学检查率。
在研究队列中,98467 名患有前列腺癌的男性(77.4%为白人;平均[SD]年龄,70.26[7.48]岁)中,57.3%为仅使用 Medicare 组,14.5%为 VA 和 Medicare 组,28.1%为仅使用 VA 组。在低危前列腺癌患者中,仅使用 Medicare 组的指南不一致性影像学检查率最高(52.5%),其次是 VA 和 Medicare 组(50.9%)和仅使用 VA 组(45.9%)(P<0.001)。高危前列腺癌患者的影像学检查率在 3 组间无显著差异。多变量分析显示,VA 和 Medicare 组(风险比[RR],0.87;95%CI,0.76-0.98)和仅使用 VA 组(RR,0.79;95%CI,0.67-0.92)患者接受指南不一致性影像学检查的可能性低于仅使用 Medicare 组。
这项研究的结果表明,与使用 VA 相比,使用 Medicare 接受医疗保健的前列腺癌患者可能会更多地利用医疗保健服务,而不会改善护理质量。